Charles River Laboratories International, Inc.

Informe acción NYSE:CRL

Capitalización de mercado: US$9.3b

Charles River Laboratories International Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Charles River Laboratories International has been growing earnings at an average annual rate of 14.1%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 11.4% per year. Charles River Laboratories International's return on equity is 11.8%, and it has net margins of 10.6%.

Información clave

14.1%

Tasa de crecimiento de los beneficios

13.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Life Sciences 21.5%
Tasa de crecimiento de los ingresos11.4%
Rentabilidad financiera11.8%
Margen neto10.6%
Próxima actualización de resultados06 Nov 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 26
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Oct 11
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

Sep 10
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Aug 10
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)

Aug 10

Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Jul 26
Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Jul 11
Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Charles River Laboratories: Fair Valuation Against Fundamentals

May 31

What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

May 25
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Apr 27
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Apr 11
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Feb 21
Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'

Feb 16

Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Jan 17
Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Jan 02
Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Dec 17
Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation

Nov 26

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Nov 12
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Charles River: Q3 Points To Ongoing Deterioration

Nov 09

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 27
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Oct 12
At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Charles River Laboratories: Diving Into The Lab (Rating Upgrade)

Oct 06

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Aug 10
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Charles River Laboratories: Very Attractive After The Pullback

Jul 26

Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Jul 22
Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

Jul 03
Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

Jun 19
When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)

May 01
A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)

Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?

Apr 16
Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?

These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well

Apr 02
These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well

Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Mar 19
Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Desglose de ingresos y gastos

Cómo gana y gasta dinero Charles River Laboratories International. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NYSE:CRL Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
29 Jun 244,0784327060
30 Mar 244,1124397390
30 Dec 234,1294757360
30 Sep 234,2164757520
01 Jul 234,1784847560
01 Apr 234,0924966850
31 Dec 223,9764866550
24 Sep 223,7814365850
25 Jun 223,6884435490
26 Mar 223,6304225780
25 Dec 213,5403915780
25 Sep 213,4263975820
26 Jun 213,2733965660
27 Mar 213,0413755280
26 Dec 202,9243645230
26 Sep 202,8243015010
27 Jun 202,7492715020
28 Mar 202,7242485200
28 Dec 192,6212524880
28 Sep 192,5322314930
29 Jun 192,4492194730
30 Mar 192,3772274560
29 Dec 182,2662254360
29 Sep 182,1431354190
30 Jun 182,0221284010
31 Mar 181,9061293770
30 Dec 171,8581233670
30 Sep 171,8461983700
01 Jul 171,8071833630
01 Apr 171,7721643570
31 Dec 161,6811543430
24 Sep 161,5681433250
25 Jun 161,4921433090
26 Mar 161,3981562880
26 Dec 151,3631502790
26 Sep 151,3391462770
27 Jun 151,3171402760
28 Mar 151,3191272740
27 Dec 141,2981282580
27 Sep 141,2571202480
28 Jun 141,2221192360
29 Mar 141,1741112260
28 Dec 131,1661042260

Ingresos de calidad: CRL has high quality earnings.

Margen de beneficios creciente: CRL's current net profit margins (10.6%) are lower than last year (11.6%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CRL's earnings have grown by 14.1% per year over the past 5 years.

Acelerando crecimiento: CRL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Beneficios vs. Industria: CRL had negative earnings growth (-10.8%) over the past year, making it difficult to compare to the Life Sciences industry average (-10.7%).


Rentabilidad financiera

Alta ROE: CRL's Return on Equity (11.8%) is considered low.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado